Mini Review
Accepted on 21 Feb 2025
The Potential Role of BCL-2 Inhibition in Amyloidosis and Plasma Cell Leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1549891
Type at least 3 characters
1,793 articles
Articles
Original Research
Published on 21 Feb 2025
Exploration of risk factors and characteristics of COVID-19 infection among patients with hematological malignancies in Suzhou, China: a retrospective study
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2024.1487516
Original Research
Published on 21 Feb 2025
Association of ANA and SSA autoantibodies with progression-free survival in multiple myeloma: a retrospective cohort study
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1529678
Review
Published on 20 Feb 2025
Influence of CAR T-cell therapy associated complications
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1494986
- 199 views
Original Research
Published on 18 Feb 2025
Prognostic value of serum lipids in newly diagnosed acute promyelocytic leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1522239
- 236 views
Original Research
Accepted on 17 Feb 2025
Associations of ANGPT2 expression and its variants (rs1868554 and rs7825407) with multiple myeloma risk and outcome
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1468373
Original Research
Published on 17 Feb 2025
Longitudinal study of cognitive and mental functions among adult Hodgkin-lymphoma survivors, based on data from a primary treatment center in Hungary
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1509424
- 236 views
Original Research
Accepted on 14 Feb 2025
Operational Procedure Sharing Pathway in Veno-Occlusive Disease: a Delphi consensus-based recommendations
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1498782
Review
Published on 14 Feb 2025
The impact of multiple myeloma drugs treatments on autologous stem cell transplantation in the era of new drugs
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1479164
- 155 views
Editorial
Accepted on 13 Feb 2025
Editorial for special research topic: elderly patients and lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1568846
Case Report
Published on 13 Feb 2025
Radiotherapy as a primary treatment modality for a young man with a primary urethral plasmacytoma: case report and literature review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1528536
- 221 views
Review
Accepted on 11 Feb 2025
Lipid Metabolism in Multiple Myeloma: Pathogenesis, Therapeutic Opportunities, and Future Directions
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1531928
Brief Research Report
Published on 11 Feb 2025
A novel truncated fusion gene ETV6::AC010198.2 in post-MPN acute myeloid leukemia caused by del(12)(p13p11)
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1495182
- 184 views
Original Research
Accepted on 10 Feb 2025
Prognostic Impact of Initial Platelet Count and Post-Induction Platelet Recovery in Elderly AML Patients: Associated with Circulating cytokines
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1534158
Original Research
Accepted on 10 Feb 2025
Retrospective study of Chidamide containing regimens as maintenance therapy among T and NK-cell lymphoma patients
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1507418
Review
Accepted on 10 Feb 2025
Advancing the Understanding and Management of Angioimmunoblastic T-cell Lymphoma: Insights into its Pathogenesis, Clinical Features, and Emerging Therapeutic Strategies
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1479179